ILMN Illumina Inc
Company Analysis
Latest News
🔴 Illumina is trading 4.1% down today amid oil-fueled risk-off sentiment
Illumina is trading 4.1% down at $271.42 amid broad risk-off sentiment, as oil prices surged after reports of tanker damage near the Strait of Hormuz and...
🟢 Illumina is trading 4.54% up today amid biotech-sector strength
Illumina is trading at $280.09, up 4.54%, amid biotech-sector strength; no confirmed Illumina-specific announcement explains the October 21 move. - XBI is up...
🔴 Illumina is trading 18.82% down in after-hours trading amid broader technology-led market losses
Illumina is trading at $213.14 (-18.82%) amid a technology-led selloff, with no confirmed company-specific catalyst. - No company-specific announcement dated...
🔴 Illumina is trading 16.21% down in after-hours trading — no clear catalyst
Illumina is trading at $224.49, down 16.21%, after the regular-session close at $267.93; the cause of the sharp after-hours drop remains unclear. - No...
🔴 Illumina is trading 5% down in after-hours trading as hotter-than-expected September inflation revives rate concerns
Illumina is trading at $254.08, down 5.17%, after-hours on October 15, with hotter-than-expected September inflation and renewed higher-for-longer rate...
🔴 Illumina is trading 4.1% down today as hotter September inflation revives rate concerns
Illumina is trading 4.14% down at $260.50, with hotter-than-expected September inflation and technology-share weakness the likeliest pressures. - Inflation...
🟢 Illumina rises 4.3% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 Illumina is trading 4.3% down
Illumina is trading at $256.29, down 4.28%, with no clear reason for the decline established in available evidence. - No verified October 8 company-specific...
🔴 Illumina is trading 5% down today as biotech stocks face pressure
Illumina is trading at $278.70, down 5.10%, as biotech stocks come under pressure. - The XBI is down 2.50% during the regular session, offering sector context...
🟢 Illumina is trading 4.5% up today, with RBC’s higher target a possible catalyst
Illumina is trading 4.51% higher at $306.93 on October 6, with RBC Capital’s target increase a likely company-specific catalyst; its direct role is...
🟢 Illumina is trading 4.05% up amid RBC Capital's price-target increase
Illumina is trading 4.05% up at $284.10, with RBC Capital’s October 5 price-target increase a likely company-specific catalyst; reporting does not confirm it...
Illumina Rallies as Leerink Raises Price Target to $300
Leerink Partners raised its price target on Illumina to $300 from $220 and maintained an Outperform rating. The move comes amid increased investor attention,...
🟢 Illumina is trading 4.6% up today on continued buying after S&P 500 inclusion
Illumina is trading 4.6% higher at $267.02, with the move most plausibly reflecting continued index-related buying after its S&P 500 inclusion. - Illumina was...
🔴 Illumina is trading 25% down in after-hours trading
Illumina is trading at $191.52, with a -25.01% change in after-hours trading; no new company-specific catalyst has been identified. - No new company-specific...
🟢 Illumina is trading 4.22% up today ahead of S&P 500 inclusion
Illumina is trading 4.22% up at $239.75, extending its recent rally as investors position for S&P 500 inclusion before the September 21, 2026 open. -...
🟢 Illumina is trading 4.35% up today ahead of S&P 500 inclusion
Illumina is trading 4.35% up now at $231.97, driven by continued buying ahead of its S&P 500 inclusion, effective before the September 21, 2026 open. -...
🟢 Illumina is trading 4.6% up today on upcoming S&P 500 inclusion
Illumina is trading 4.6% up at $217.78, supported by continued momentum ahead of its S&P 500 inclusion, effective before the September 21, 2026 open. - UBS...
Illumina Upgraded to Buy as UBS Nearly Doubles Price Target to $260
UBS upgraded Illumina (ILMN) from Neutral to Buy on September 9, 2026. The firm increased its price target for the stock to $260 from $135. This new target...
Triple Frond Partners Exits Entire Stake in Illumina (ILMN)
Major investor Triple Frond Partners sold its entire position in genetics sequencing leader Illumina Inc. (ILMN) during the second quarter of 2026. The firm...
🔴 Illumina falls 4.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...